Liquidia Corporation
- Jurisdiction
United States - LEI
549300O826O5VQJTG707 - ISIN
US53635D2027 (LQDA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Read full profile
Fundamentals
- Net revenue
€16.48M - Gross margin
70.4% - EBIT
-€117.90M - EBIT margin
-715.4% - Net income
-€85.20M - Net margin
-517.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| SINGH RAMAN | N/A |
|
|
|
|
| Adair Jason | Chief Business Officer |
|
|
|
|
| Kaseta Michael | CFO and COO |
|
|
|
|
| Manning Paul B | N/A |
|
|
|
|
| Moomaw Scott | Chief Commercial Officer |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 14, 2024 (Q1 2024)